Page 50 - EJMO-9-1

Eurasian Journal of Medicine and
Oncology
BRCA VUS in breast cancer in MENA region

influencing BC susceptibility in this region, paving the way mutations. J Natl Cancer Inst. 2003;95(6):448-457.
for improved patient outcomes and tailored interventions. doi: 10.1093/jnci/95.6.448
Acknowledgments 6. Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and
BRCA2 mutation carriers: Results from prospective analysis
None. of EMBRACE. J Natl Cancer Inst. 2013;105(11):812-822.
Funding doi: 10.1093/JNCI/DJT095

None. 7. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong
candidate for the breast and ovarian cancer susceptibility
Conflict of interest gene BRCA1. Science. 1994;266(5182):66-71.

The authors declare that they have no competing interests. doi: 10.1126/science.7545954
8. Wooster R, Bignell G, Lancaster J, et al. Identification
Author contributions of the breast cancer susceptibility gene BRCA2. Nature.
Conceptualization: Oubaida Elbiad, Abdelilah Laraqui 1995;378(6559):789-792.
Formal analysis: Oubaida Elbiad, Bouabid Badaoui, doi: 10.1038/378789a0
Oumaima Mazour 9. Domchek SM, Weber BL. Clinical management of BRCA1 and
Writing – original draft: Oubaida Elbiad, Abdelilah Laraqui BRCA2 mutation carriers. Oncogene. 2006;25(43):5825-5831.
Writing – review & editing: Oubaida Elbiad, Abdelilah
Laraqui, Khalid Ennibi doi: 10.1038/SJ.ONC.1209881
10. Lindor NM, Guidugli L, Wang X, et al. A review of a
Ethics approval and consent to participate multifactorial probability-based model for classification
of BRCA1 and BRCA2 variants of uncertain significance
Not applicable.
(VUS). Hum Mutat. 2012;33(1):8-21.
Consent for publication doi: 10.1002/humu.21627
Not applicable. 11. Cragun D, Dean M, Baker D, et al. The development and
evaluation of novel patient educational material for a variant
Availability of data of uncertain significance (VUS) result in hereditary cancer
genes. Curr Oncol. 2024;31(6):3361-3378.
Data are available on reasonable request by contacting the
corresponding author directly. doi: 10.3390/curroncol31060256
12. Slavin TP, Manjarrez S, Pritchard CC, Gray S, Weitzel JN.
References The effects of genomic germline variant reclassification on
1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics clinical cancer care. Oncotarget. 2019;10(4):417-423.
2022: GLOBOCAN estimates of incidence and mortality doi: 10.18632/oncotarget.26501
worldwide for 36 cancers in 185 countries. CA Cancer J Clin.
2024;74:229-263. 13. Bozsik A, Papp J, Grolmusz VK, Patócs A, Oláh E, Butz H.
Reclassification of Five BRCA1/2 variants with unknown
doi: 10.3322/caac.21834 significance using complex functional study. Cancer Res
2. Elengoe A. A short review on breast cancer. Int J Biotechnol Treat. 2022;54(4):970-984.
Biomed. 2024;1(1):1-11. doi: 10.4143/crt.2021.1078
doi: 10.31674/ijbb.2024.v01i01.001 14. Richards S, Aziz N, Bale S, et al. Standards and guidelines for
3. World Health Organisation. Latest Global Cancer Data : the interpretation of sequence variants: A joint consensus
Cancer Burden Rises to 18. 1 Million New Cases and 9. 6 recommendation of the American College of Medical
Million Cancer Deaths in 2018. France: International Agency Genetics and Genomics and the Association for Molecular
for Research on Cancer; 2018. p. 13-15. Pathology. Genet Med. 2015;17(5):405-424.
4. Safiri S, Noori M, Nejadghaderi SA, et al. Burden of female doi: 10.1038/gim.2015.30
breast cancer in the Middle East and North Africa region, 15. Tazzite A, Jouhadi H, Nadifi S, et al. BRCA1 and BRCA2
1990–2019. Arch Public Health. 2022;80(1):168.
germline mutations in Moroccan breast/ovarian cancer
doi: 10.1186/s13690-022-00918-y families: Novel mutations and unclassified variants. Gynecol
Oncol. 2012;125(3):687-692.
5. Dite GS, Jenkins MA, Southey MC, et al. Familial risks,
early-onset breast cancer, and BRCA1 and BRCA2 germline doi: 10.1016/j.ygyno.2012.03.007

Volume 9 Issue 1 (2025) 42 doi: 10.36922/ejmo.5800